evidence: Moderna COVID-19 Vaccine (2024-2025 Formula) Authorized For Individuals 6 Months through 11 Years of Age On August 22, 2024, the Food and Drug Administration amended the emergency use authorization (EUA) of Moderna COVID-19 Vaccine to include the 2024-2025 formula. The Moderna COVID-19 Vaccine (2024-2025 Formula) includes a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The Moderna COVID-19 Vaccine (2024-2025 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19. Moderna COVID-19 Vaccine (2024-2025 Formula) is authorized for use as follows: